Editor – We were concerned that a new treatment for tuberculosis (TB) was being advocated without the benefit of a randomised controlled trial (W Saeed, Clin Med February 2012 pp 40–1). The authors argue that cavitary pulmonary TB relapses following therapy in 21–25% of cases and that
No takes yet. Share an insight, caveat, or question.
Bothamley et al. (2012) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: